2019台灣生技月 Bio Taiwan 生物科技大展

2019 台灣生技月 南港展覽館

講師

Atsushi Hasuoka


Session 5 – Regional Collaboration & Opportunity
Date: 25 July (Thursday)  09:00 – 12:15
Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
 


 

Atsushi Hasuoka
Senior Director
Takeda Pharmaceutical Company Limited

Vice Chair of R&D Subcommittee 
Japan Pharmaceutical Manufactures Associations (JPMA)

 
Dr. Atsushi Hasuoka is the Head of Innovation Promotion, Shonan Research Central Office Takeda Pharmaceutical Company Limited; Vice Chairman of R&D Subcommittee, Japan Pharmaceutical Manufactures Association (JPMA) and the leader of Asia Pacific Conference of Pharmaceutical Associations (APAC) Drug Discovery Alliances Expert Working Group (DAEWG).
 
Dr. Hasuoka has more than 20-year career in the pharmaceutical industry. He started his career in Takeda as a medicinal chemist. In the career of researcher he was involved in a research project to explore a new proton pump inhibitor (PPI). In this project he contributed to development of TAKECAB® , a new PPI with a novel mechanism of action called potassium competitive acid blocker. He changed his career from a researcher to a research manager about 10 years ago. In his career of research manager he held the position of Shonan Site Head of Oncology Drug Discovery Unit. He is now the head of an office called “Innovation Promotion” whose mission is to advance drug discovery by leveraging open innovation in Japan as well as in Asian countries.
 
Dr. Hasuoka participated in the activity of JPMA as a Chairman of JPMA R&D Subcommittee in 2015. He was appointed to the leader of APAC DAEWG in 2016. Since then he has tried to promote cross-border open innovation in collaboration with group members from other Asian countries. Last December, APAC DAEWG achieved launch of APAC natural Product Drug Discovery Consortium, a consortium aimed at maximizing the potential of natural product in drug discovery.
 
Dr. Hasuoka obtained the degree of Master of Chemistry from Osaka University and Doctor of Pharmaceutical Science from Tokyo University of Science. He researched as a postdoctoral fellow under the guidance of professor John L. Wood at Yale University. He completed Executive MBA program of NUCB Business School.

 
Session Speech Title & Synopsis:
How to promote cross-border open innovation in Asia for drug discovery
Open Innovation has become a norm in the pharmaceutical industry. And then, we have come to see and hear "drug discovery ecosystem" these days. This term represents a situation where many players in the drug discovery have productive networks with each other and collaborate in a synergistic way. Drug discovery ecosystem is critical in terms of sustainable generation of innovative drugs to patents who are waiting for them.
 
When we look at Asia from the viewpoint of drug discovery ecosystem we recognize that Asia has some unique advantages over other regions in the world. Asian counties have fostered many key players of the ecosystem such as academia, research organizations, bioventures and pharmaceutical companies. In addition, those key players are located within three-hour time difference. On the other hand, Asia accounts for approximately 60% of world population now and many of Asian countries are on the way of economic growth. These demographic and economic trends in Asia suggest even stronger demand for innovative drugs in this region in the near future.
 
Asia Partnership Conference of Pharmaceutical Associations (APAC) is an Asian-wide initiative to enhance relationships among the pharmaceutical industry associations aiming at realizing APAC mission "To expedite the launch of innovative medicines for the peoples in Asia". As one of the three working groups in APAC, Drug Discovery Alliance Expert Working Group (DAEWG) has been working on promotion of the cross-border open innovation in collaboration with group members from various Asian countries. In this session, Atsushi Hasuoka, a leader of DAEWG, will talk about how the team has tried to promote cross-border open innovation in Asia